Oklo stock trades near $49 after the U.S. Department of Energy approved the Documented Safety Analysis for the company’s Groves Isotope Test Reactor in Texas on July 1, marking a critical milestone for the advanced nuclear technology firm.
The DSA approval represents the final safety basis for Groves and follows an earlier Preliminary Documented Safety Analysis approval. With both in place, the facility moves into DOE’s final pre-startup review phase. The remaining steps are DOE’s readiness review and startup approval, after which Groves can receive nuclear fuel and proceed toward first criticality. Oklo is targeting first criticality for July 2026, a deadline set by the DOE’s Reactor Pilot Program.
Oklo co-founder and CEO Jacob DeWitte stated that Groves is the first advanced reactor project to receive DSA approval on privately owned land, with wholly commercially sourced fuel, equipment, and systems delivered by the private sector. The facility broke ground less than a year ago and supports Oklo’s isotope business, aiming to establish a domestic supply chain for critical isotopes used in cancer diagnosis and treatment, scientific research, and national security applications.
The DOE approval came as part of a broader federal initiative to accelerate advanced reactor deployment. In August 2025, the DOE selected 11 advanced reactor projects for its Reactor Pilot Program, with the goal of achieving criticality in at least three test reactors by July 4, 2026. Oklo’s Groves facility is among the frontrunners in this race, and the DSA approval removes a major regulatory hurdle.
Oklo stock has been volatile, with shares trading in a 52-week range of $44.80 to $193.84. The stock is down 28% year-to-date, but the DOE approval has provided momentum—shares rose roughly 4% in the five trading days following the announcement. On July 10, 2026, the stock closed at $48.85, down 0.85% on the day.
Wall Street analysts remain cautiously optimistic. According to Barchart analysis, Oklo holds a consensus “Moderate Buy” rating with a 12-month average price target of $84.10, implying potential upside of about 62% from current levels. JPMorgan analysts described the company’s quarterly progress as illustrating steady advancement, though the real catalyst will come when Groves reaches criticality and transitions from concept to operational reality.
The company reported a first-quarter 2026 loss of $0.19 per share, in line with analyst expectations, while construction milestones at Groves remain on track. Wall Street currently forecasts approximately $1.16 million in revenue for 2026, as Oklo remains largely pre-revenue while advancing its reactor and isotope businesses. Commercial revenue is expected to depend heavily on key milestones, including bringing Groves online and progressing its broader deployment pipeline. The global nuclear market opportunity is estimated at approximately $10 trillion, with small modular reactor technology projected to reach a growth inflection point between 2030 and 2035, driven by surging electricity demand from data-center infrastructure.
Sources
- Oklo Inc. (official press release) — DOE approval of Documented Safety Analysis for Groves Isotope Test Reactor, July 1, 2026.
- Investing.com — Oklo stock rises after DOE approves reactor safety analysis; CEO Jacob DeWitte quote on first-mover status.
- Yahoo Finance / Barchart — Analyst consensus rating, price target, stock performance, and quarterly earnings context.
- CNN, MarketWatch, Macrotrends — Stock price data and 52-week range as of July 10, 2026.
- Interesting Engineering — Groves reactor targeting July 2026 first criticality milestone.
